Venous access ports: frequency and management of complications in oncology patients
- PMID: 18596390
- DOI: 10.1159/000140451
Venous access ports: frequency and management of complications in oncology patients
Abstract
Totally implantable venous access ports have been in use now for over 20 years. They are valuable instruments for long-term intravenous treatment of patients with cancer. Apart from perioperative difficulties, the typical complications associated with venous access ports are venous thrombosis, port infection, extravasation, pinch off syndrome, dislocation, occlusion and catheter leakages. The vast majority of these complications are avoidable, or at least the complication rate can be reduced with health care personnel training and education of patients. This review will give a broad overview on the frequency and possible complications related to port devices. Furthermore, this review suggests strategies for management including proposals to avoid such complications.
(c) 2008 S. Karger AG, Basel
Similar articles
-
Advances in venous access devices and nursing management strategies.Nurs Clin North Am. 1990 Jun;25(2):345-64. Nurs Clin North Am. 1990. PMID: 2110664 Review.
-
[Complications of central venous and indwelling catheterization].Rev Prat. 2006 Jun 30;56(12):1281-9. Rev Prat. 2006. PMID: 16948214 Review. French.
-
Totally implantable central venous access ports. Analysis of 700 cases.J Surg Oncol. 2011 Nov 1;104(6):654-6. doi: 10.1002/jso.21990. Epub 2011 Jun 13. J Surg Oncol. 2011. PMID: 21671465
-
[Totally implantable venous access ports: frequency of complications and analysis of bacterial contamination after ablation].Pathol Biol (Paris). 2004 Dec;52(10):566-74. doi: 10.1016/j.patbio.2004.07.020. Pathol Biol (Paris). 2004. PMID: 15596304 French.
-
Totally implantable venous-access ports: local problems and extravasation injury.Lancet Oncol. 2002 Nov;3(11):684-92. doi: 10.1016/s1470-2045(02)00905-1. Lancet Oncol. 2002. PMID: 12424071 Review.
Cited by
-
[Antineoplastic drug-induced extravasation].Med Klin (Munich). 2010 Nov;105(11):812-24. doi: 10.1007/s00063-010-1139-y. Med Klin (Munich). 2010. PMID: 21136240 Review. German. No abstract available.
-
A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.Drug Des Devel Ther. 2015 Nov 11;9:6067-73. doi: 10.2147/DDDT.S94901. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26648694 Free PMC article. Clinical Trial.
-
Central venous port systems as an integral part of chemotherapy.Dtsch Arztebl Int. 2011 Mar;108(9):147-53; quiz 154. doi: 10.3238/arztebl.2011.0147. Epub 2011 Mar 4. Dtsch Arztebl Int. 2011. PMID: 21442071 Free PMC article.
-
Is there any effect of first-day usage of a totally implantable venous access device on complications?Int J Clin Oncol. 2015 Dec;20(6):1057-62. doi: 10.1007/s10147-015-0830-7. Epub 2015 Apr 25. Int J Clin Oncol. 2015. PMID: 25911604
-
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.Int J Clin Oncol. 2015 Apr;20(2):332-7. doi: 10.1007/s10147-014-0703-5. Epub 2014 May 10. Int J Clin Oncol. 2015. PMID: 24811333
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical